Role of vitamin D in the immune system;D vitamininin immun sistemdeki rolu

Turkish Journal of Endocrinology and Metabolism

Volumn 17, Issue 1, 2013, Pages 5-7

  Tamer, Gonca ^a   Mesçi, Banu ^a  

^a Sb Medeniyet University Goztepe Education and Research Hospital   (Turkey)

Author keywords

1,25(OH)2D3; Dendritic cell; Immune system; T cell; Vitamin D

Indexed keywords

CALCITRIOL; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSFORMING GROWTH FACTOR; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; APOPTOSIS; ARTICLE; B LYMPHOCYTE; BACTERICIDAL ACTIVITY; CELL DIFFERENTIATION; CELL MATURATION; CYTOKINE PRODUCTION; DENDRITIC CELL; DOWN REGULATION; HUMAN; IMMUNOREGULATION; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; PHAGOCYTOSIS; PHENOTYPE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH2 CELL;

EID: 84875544222     PISSN: 13012193     EISSN: 13089846     Source Type: Journal    
DOI: 10.4274/Tjem.1938     Document Type: Article

References (37)

1. Holick MF. Resurrection of vitamin D deficiency and rickets. J Clin Invest 2006;116:2062-2072.
2. Holick MF, Garabedian M. Vitamin D: photobiology, metabolism, mechanism of action, and clinical applications. In: Favus MJ, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism (6 th ed). Washington; American Society for Bone and Mineral Research;2006;129-137.
3. Bouillon R. Vitamin D: from photosynthesis, metabolism, and action to clinical applications Endocrinology. In: DeGroot LJ, Jameson JL eds. Philadelphia; WB Saunders,2001;1009-1028.
4. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin 2004;80(Suppl):1689-1696.
5. Michael F, Holick MF. Vitamin D defi ciency. N Engl j Med 2007;357:266-281.
6. Deluca HF, Cantorna MT. Vitamin D: its role and uses in immunology. FASEB J 2001;15:2579-2585.
7. Cantorna MT, Zhu Y, Froicu M, Wittke A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr 2004;80:1717-1720.
8. Van Etten E, Mathieu C. Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 2005;97:93-101.
9. Veldman, CM, Cantorna MT, DeLuca HF. Expression of 1,25 dihydroxyvitamin D(3) receptor in the immune system. Arch. Biochem Biophys 2000;374:334-8.
10. Overbergh L, Decallonne B, Valckx D, et al. Identifi cation and immune regulation of 25-hydroxyvitamin D-1-alpha-hydroxylase in murine macrophages. Clin Exp Immunol 2000;120:139-146.
11. Alemzadeh R, Kichler J, Babar G, Calhoun M. Hypovitaminosis D in obese children and adolescents: relationship with adiposity, insulin sensitivity, ethnicity, and season. Metabolism 2008;57:183-191.
12. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(Suppl 6):1678-1688.
13. Reis AF, Hauache OM, Velho G. Vitamin D endocrine system and the genetic susceptibility to diabetes, obesity and vascular disease. A review of evidence. Diabetes Metab 2005;31:318-325.
14. Kadowaki S, Norman AW. Time course study of insulin secretion after 1,25-dihydroxyvitamin D3 administration. Endocrinology 1985;117:1765-1771.
15. Lee S, Clark SA, Gill RK, Christakos S.,25-Dihydroxyvitamin D3 and pancreatic beta-cell function: vitamin D receptors, gene expression, and insulin secretion. Endocrinology 1994; 134:1602-1610.
16. Scragg R, Holdaway I, Singh V, et al. Serum 25-hydroxyvitamin D3 levels decreased in impaired glucose tolerance and diabetes mellitus. Diabetes Res Clin Pract 1995;27:181-8.
17. Hyppönen E, Power C. Vitamin D status and glucose homeostasis in the 1958 British birth cohort: the role of obesity. Diabetes Care 2006;29:2244-2246.
18. Maggio CA, Pi-Sunyer FX. The prevention and treatment of obesity. Application to type 2 diabetes. Diabetes Care 1997;20:1744-1766.
19. Rodríguez-Rodríguez E, Navia B, López-Sobaler AM, Ortega RM. Vitamin D in overweight/obese women and its relationship with dietetic and anthropometric variables. Obesity (Silver Spring) 2009;17:778-7782.
20. McGill AT, Stewart JM, Lithander FE, Strik CM, Poppitt SD. Relationships of low serum vitamin D3 with anthropometry and markers of the metabolic syndrome and diabetes in overweight and obesity. Nutr J 2008;7:4.
21. Ford ES, Ajani UA, McGuire LC, Liu S. Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care 2005;28:1228-1230.
22. Vilarrasa N, Maravall J, Estepa A, et al. Low 25-hydroxyvitamin D concentrations in obese women: their clinical signifi cance and relationship with anthropometric and body composition variables. J Endocrinol Invest 2007;30:653-658.
23. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-825.
24. Tamer G, Arik S, Tamer I, Coksert D. Relative vitamin D insuffi ciency in Hashimoto's thyroiditis. Thyroid 2011;21:891-896.
25. Tamer G, Mesci B, Tamer I, Kilic D, Arik S. Is vitamin D defi ciency an independent risk factor for obesity and abdominal obesity in women? Endokrynol Pol 2012;63:196-201.
26. Mahon BD, Wittke A, Weaver V, Cantorna MT. The targets of vitamin D depend on the differentiation and activation status of CD4 positive T cells. J Cell Biochem 2003;89:922-932.
27. Bemiss CJ, Mahon BD, Henry A, Weaver V, Cantorna MT. Interleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune system. Arch Biochem Biophys 2002;402:249-254.
28. Cantorna MT, Humpal-Winter J, DeLuca HF. In vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D(3). Arch Biochem Biophys 2000;377:135-138.
29. Abe E, Miyaura C, Sakagami H, et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proc Natl Acad Sci USA 1981;78:4990-4994.
30. Tanaka H, Abe E, Miyaura C, et al. 1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). Biochem J 1982;204:713-719.
31. Cantorna MT. Vitamin D and autoimmunity: is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med 2000;223:230-233.
32. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008;624:55-71.
33. van Etten E, Decallonne B, Bouillon R, Mathieu C. NOD bone marrow-derived dendritic cells are modulated by analogs of 1,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol 2004;89-90:457-459.
34. Bischoff-Ferrari HA. Optimal serum 25-hydroxyvitamin D levels for multiple health outcomes. Adv Exp Med Biol 2008;624:55-71.
35. Overbergh L, Decallonne B, Waer M, et al. 1alpha,25-dihydroxyvitamin D3 induces an autoantigen-specifi c T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524-543). Diabetes 2000;49:1301-1307.
36. Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L. A 1alpha,25-dihydroxyvitamin D(3) analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 2002;51:1367-1374.
37. Chen S, Sims GP, Chen XX, et al. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007;179:1634-1647.